Aperçu du dossier

Introduction

In a significant development for liquid biopsy and genomic diagnostics patent litigation, the U.S. Court of Appeals for the Federal Circuit issued a vacatur and remand in Guardant Health, Inc. v. University of Washington (Case No. 24-1129), a dispute centered on the patentability of duplex consensus sequencing — a foundational methodology for reducing error rates in massively parallel DNA sequencing. Filed on November 7, 2023, and closed on January 23, 2026, after 808 days of proceedings, this case carries substantial implications for biotech patent holders, genomic diagnostics companies, and R&D teams navigating freedom-to-operate risk in next-generation sequencing technologies.

The Federal Circuit’s decision to vacate and remand — rather than affirm or reverse outright — signals unresolved legal questions about patent validity that lower proceedings must now reexamine. For patent attorneys, in-house IP counsel, and life sciences innovators, this outcome merits careful analysis.

Les parties

Le brevet en cause

• • Patent No.: US10760127B2 (Application No. US16/503382)
• • Technology: Methods of lowering the error rate of massively parallel DNA sequencing using duplex consensus sequencing
• • Core Claims (Plain Language): The patent covers sequencing methods that generate consensus sequences from both strands of a DNA duplex, dramatically reducing error rates inherent in high-throughput sequencing — a critical capability for detecting rare mutations in liquid biopsy applications

Représentation juridique

Plaintiff (Guardant Health): Orrick, Herrington & Sutcliffe LLP and Wilson, Sonsini, Goodrich & Rosati, PC — represented by a nine-attorney team including E. Joshua Rosenkranz, Michael T. Rosato, and Ph.D.-credentialed counsel Sonja Rochelle Gerrard.

Defendant (University of Washington): Sterne, Kessler, Goldstein & Fox, PLLC — represented by Byron Leroy Pickard, Ralph Wilson Powers III, and colleagues, a firm recognized for its deep PTAB and appellate IP practice.

Chronologie du litige et historique de la procédure

The case was filed directly at the appellate level with the Federal Circuit — the exclusive appellate venue for U.S. patent matters — indicating this dispute arose from a lower-level proceeding, most likely a USPTO inter partes review (IPR) or ex parte reexamination, consistent with the verdict cause of Invalidity/Cancellation Action. The 808-day duration reflects the complexity typical of Federal Circuit patent appeals involving technical subject matter in molecular biology and genomics, where extensive briefing, expert declarations, and en banc considerations can extend timelines considerably. No chief judge assignment was noted in the case record.

Le verdict et l'analyse juridique

Résultat

The Federal Circuit ordered: VACATED AND REMANDED. This outcome does not constitute a final win for either party. The appellate court declined to sustain the lower tribunal’s ruling on patentability, instead directing that the matter be reconsidered under corrected legal standards or with additional factual development.

Specific damages were not applicable at this appellate stage, as the proceeding centered on invalidity/cancellation rather than infringement damages. No injunctive relief was at issue.

Analyse des causes du verdict

The verdict cause is identified as Patentability — Invalidity/Cancellation Action, strongly suggesting this Federal Circuit appeal arose from a USPTO post-grant proceeding (likely IPR) challenging the validity of US10760127B2. In such proceedings, petitioners challenge patent claims on grounds including anticipation (35 U.S.C. § 102) or obviousness (35 U.S.C. § 103).

A vacatur and remand from the Federal Circuit in a patentability appeal typically occurs when:

• Legal error in claim construction — The lower tribunal applied an incorrect standard for interpreting claim terms, affecting validity determinations
• Inadequate factual findings — The Patent Trial and Appeal Board (PTAB) or district court failed to adequately address secondary considerations of non-obviousness, such as long-felt need, commercial success, or unexpected results
• Procedural deficiency — The tribunal exceeded its authority, addressed claims not properly before it, or failed to provide sufficient reasoning under Motor Vehicle Mfrs. Ass’n v. State Farm administrative law standards

Given the technical complexity of duplex consensus sequencing — which represents a genuine methodological innovation in error-corrected NGS — the obviousness analysis would necessarily involve sophisticated prior art comparisons. The Federal Circuit’s decision to vacate rather than affirm suggests the lower proceeding’s invalidity analysis was legally incomplete or improperly reasoned.

Signification juridique

This case reinforces that method claims covering DNA sequencing techniques remain highly litigable terrain at the Federal Circuit. The vacatur preserves the patent’s viability while requiring further scrutiny — a procedurally significant outcome for UW as patent holder and for Guardant Health as the challenging party.

For practitioners, the case highlights ongoing tension in obviousness determinations for biotech methods where prior art may disclose component steps, but the combination and resulting error-reduction utility may constitute non-obvious innovation. The duplex consensus sequencing methodology at issue was pioneered in academic literature, making the intersection of published research and patent rights particularly nuanced.

Points stratégiques à retenir

For Patent Holders (University of Washington, academic institutions):

• A vacatur is not a loss — it reopens validity proceedings with an opportunity to correct legal framing and bolster non-obviousness arguments with stronger secondary consideration evidence
• Academic patent portfolios asserting foundational research methods should proactively develop commercial success and licensing adoption records to support non-obviousness on remand

For Patent Challengers (Guardant Health, genomic diagnostics companies):

• Invalidity challenges to method patents in sequencing technology require airtight prior art mapping at the claim element level
• When appealing IPR decisions, ensure the record fully addresses all claim construction positions — Federal Circuit vacaturs frequently turn on inadequate lower-level reasoning that challengers may not have anticipated

Pour les équipes de R&D :

• Companies developing error-corrected sequencing workflows should conduct updated freedom-to-operate (FTO) analyses following the remand, as US10760127B2 remains a live patent with unresolved validity status
• Design-around strategies focusing on single-strand consensus approaches or alternative error-correction methodologies may reduce exposure pending final resolution

Implications pour l'industrie et la concurrence

The Guardant Health v. University of Washington dispute sits at the intersection of two high-stakes dynamics: academic IP commercialization and competitive liquid biopsy market positioning. Duplex consensus sequencing underpins a class of highly sensitive diagnostic assays where sequencing error rates directly determine clinical utility. Patent control over such foundational methods carries significant licensing leverage.

For the broader next-generation sequencing (NGS) and liquid biopsy industry, this case signals continued aggressive patent enforcement around core sequencing methodologies. Companies including Illumina, Pacific Biosciences, Foundation Medicine, and emerging liquid biopsy entrants should monitor the remand outcome closely, as the final validity determination of US10760127B2 will define the licensing landscape for duplex consensus approaches.

The case also reflects a broader trend of universities asserting foundational biotech patents against commercial entities that have built product lines on related research — a dynamic seen across genomics, CRISPR, and mRNA technology sectors. IP teams at diagnostics and genomics companies should anticipate similar challenges and maintain robust prior art libraries and prosecution histories.